Commissioner-designate Jane Henney signals continuity in centers management.
This article was originally published in The Tan Sheet
Executive Summary
FDA COMMISSIONER NOMINEE HENNEY SIGNALS CONTINUITY, suggesting there will be stability in top-side agency support for the agency's six operating centers. Jane Henney, MD, lists recruiting five of the six center directors among her major accomplishments during her first tour of duty at FDA as deputy commissioner for operations from 1992-1994. The physician directors of the Centers for Drug Evaluation & Research (Janet Woodcock), Biologics Evaluation & Research (Kathryn Zoon) and Devices & Radiologic Health (Bruce Burlington) all were appointed to their positions during Henney's tenure.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning